BACKGROUND The comparative effectiveness of percutaneous closure of patent foramen ovale (PFO) plus medical
the data have been contradictory as to the statistical significance of these associations (1) (2) (3) (4) (5) . We performed a meta-analysis of individual participant data to better synthesize data from the 3 randomized trials (6) (7) (8) .
Individual participant data meta-analysis holds several advantages over meta-analysis using aggregate results extracted from trial publications (9) , including the ability to standardize outcome definitions and analyses across studies without any reliance on numerical approximations, which are often necessary when extracting data from publications. Additionally, access to participant-level data allows the use of statistical methods to address missing data, perform covariate-adjusted analyses (which often have greater power than unadjusted analyses for time-to-event outcomes [10] [11] [12] ), and assess heterogeneity of treatment effects across subgroups.
METHODS
We pre-specified our analytical plan and registered the study protocol with PROSPERO, the international prospective register of systematic reviews (CRD42014013895). The Tufts Medical Center Institutional Review Board approved the study.
We used individual participant data from 3 randomized trials that, to our knowledge, represent the totality of randomized evidence on percutaneously implanted PFO closure devices versus medical therapy in patients with PFO and cryptogenic stroke. The CLOSURE I trial (6) For time-to-event analyses, we obtained KaplanMeier estimates (15) and tested the equality of the survivor functions using the log-rank test stratified by trial. We obtained estimates of the hazard ratio (HR) comparing treatment groups using Cox proportional hazard regression stratified by trial with no covariate adjustment (16) . In this analysis, we assumed that each study had a different baseline hazard and that the treatment effect was common across trials. We chose this model because the number of available studies was small, simulation studies at the planning stage indicated that it had reasonable statistical performance, and it is consistent with the statistical analyses performed within each study.
We also performed Cox proportional hazard regression analyses adjusted for the following covariates: age, sex, coronary artery disease, diabetes, hypertension, hyperlipidemia, prior stroke, smoking status, hypermobile septum, and PFO shunt size (large vs. small). Covariates were selected on the basis of prior work suggesting that they predicted stroke recurrence or a PFO-related mechanism in the
RoPE (Risk of Paradoxical Embolism) score (17, 18) .
We used multiple imputation to address missing data in covariates used in adjusted and subgroup analyses.
For safety outcomes, we reported procedural complications in the device arms and, for AF and bleeding events, estimated unadjusted HRs comparing treatment groups using Cox regression stratified by trial.
We assessed heterogeneity of treatment effects across levels of baseline characteristics by repeating the efficacy analyses described in the previous text, including appropriate interactions in Cox regressions.
Herein, we report pre-specified subgroups on the basis of age, sex, smoking status, and PFO anatomical features (shunt size and presence of atrial septal aneurysm). One additional subgroup analysis on the basis of the qualifying event (stroke vs. TIA) was added during revision. Planned subgroup analyses on the basis of the RoPE score and variations of the score that incorporate recurrence risk will be described in a separate report.
We repeated the analyses described in the previous text (stratified log-rank tests and unadjusted and adjusted stratified Cox regressions) using only data from the 2 disc occluder trials (i.e., excluding data from the CLOSURE I trial). We also performed stability analyses after excluding each of the other trials in turn.
We defined 2-sided p values <0.05 as statistically significant. All analyses were performed using SAS version 9.4 TS Level 1MI (SAS/Stat 13.1) (SAS Institute, Cary, North Carolina).
RESULTS
This patient-level pooled analysis included data from 2,303 randomized patients followed for a total of 5,849 person-years. Overall, 442 patients (263 in the medical therapy arm; 171 in the device arm) withdrew or were otherwise lost to follow-up before study termination. Characteristics of patients are seen across trials ( Table 1 ) and treatments ( Table 2 ). There were some minor differences across trials. The PC trial had a higher prevalence of smoking and prior stroke, but a lower prevalence of other vascular risk factors (i.e., diabetes, hypercholesterolemia, or hypertension). Qualifying infarcts in the RESPECT trial were more frequently located superficially on neuroimaging than in CLOSURE I. (Infarct location was unavailable in the PC trial.) The PC trial had a higher proportion of patients receiving anticoagulation (instead of antiplatelet) therapy in the medical arm and a lower prevalence of putative highrisk anatomic PFO features (i.e., large shunt or hypermobile interatrial septum) than the other trials.
Covariates were generally balanced across treatment groups, except that patients assigned to device closure were slightly more likely to have large PFOs.
A total of 108 composite endpoint events (ischemic stroke/TIA/death) were observed, including 58 ischemic strokes (56 as first events), 54 TIAs (48 as first events), and 7 deaths (4 as first events; 4 classified as early deaths). The rate of stroke was 0.98 per 100 person-years across both arms; the composite event rate was 1.8 per 100 person-years. Annualized event rates by treatment arm are shown in Table 3 .
Results from trial-specific analyses are shown in Online Table 1 .
The Central Illustration depicts Kaplan-Meier curves for the primary composite outcome and stroke alone. As shown in Table 3 Table 3) . Table 3 , all analyses for the stroke outcome showed that device closure plus medical therapy was significantly more effective than medical therapy alone, with the unadjusted and adjusted an- As-treated analyses produced point estimates more favorable for closure compared with ITT analyses and were statistically significant for all outcomes, both Kent 
As shown in
when all trials were pooled and when analyses were limited to the 2 disc occluder trials ( Table 4) . Results for safety outcomes are summarized in Table 5 . The hazard of AF among patients receiving closure was 3 times as high as that among patients receiving medical therapy (HR: 3.22; 95% CI: 1.76 to 5.90; p < 0.0002). In analyses restricted to the disc occluder trials, the HR for AF was 1.85 (95% CI: 0.86 to 3.98; p ¼ 0.117). Bleeding rates were not statistically different between treatment groups. Online Table 2 shows safety outcomes analyzed by ITT.
Finally, in stability analyses excluding either of the disc occluder trials (i.e., pairing CLOSURE I with either RESPECT or the PC trial), treatment effects were no longer statistically significant (Online Table 3 ).
DISCUSSION
Our study indicates that patients <60 years of age found to have a PFO in the setting of a cryptogenic ischemic stroke have relatively low stroke recurrence rates whether treated with percutaneous device therapy or with medical therapy. Outcome rates were generally lower with percutaneous closure plus medical therapy than with medical therapy alone (Central Illustration); the difference between the 2 treatments was consistently significant for the secondary efficacy outcome of ischemic stroke and for the primary composite outcome in adjusted but not unadjusted analyses.
We interpret these results, on the basis of the totality of available randomized data and all analyses performed, as providing evidence that closure can prevent stroke recurrence in some patients with cryptogenic stroke found to have a PFO. However, AF is increased with closure, although less strongly with the disc occluder device. These findings suggest that closure with the disc occluder is a reasonable therapeutic option in the context of informed decision making. Informally, for patients similar to those enrolled in the trials, the annualized rate of ischemic stroke, if treated medically, is approximately 1%; device closure decreases this rate by one-half.
Although there is uncertainty in the estimates, to avert 1 primary composite outcome event, the number needed to treat over 2.5 years was 50, and to avert 1 ischemic stroke, the number needed to treat was 67.
A benefit of this magnitude may be clinically important to some patients and may continue beyond 2.5 years among younger stroke patients with a long life expectancy. We stress that our study results may not be applicable to other devices, particularly non-PFO devices that are being used off-label for PFO closure.
Although bleeding rates were similar between device and medical therapy arms, rates of AF increased with device closure in the overall analysis.
The difference did not reach statistical significance for the disc occluder device, for which point estimates Although the effects estimated in our analysis were substantial on the relative-risk scale, and the estimated reduction in absolute risk may be of clinical import, they were smaller than those anticipated in the power calculation of the individual trials. For example, the RESPECT trial was powered to detect a 75% relative risk reduction and the PC trial was powered to detect an absolute effect of >2%/year.
Research completed since the planning of these trials Values are % (n), mean AE SD (n), or % (n/N) of patients with available data. *Findings on transesophageal echocardiography.
Abbreviations as in Table 1 . has shown that a substantial proportion of index cryptogenic strokes in patients with PFO may be due to mechanisms unrelated to PFO (18, 19) . Studies have additionally suggested that paradoxical embolism may be a mechanism with an especially low recurrence risk; thus, even in patients with such PFOrelated mechanisms, recurrent events may often be unrelated to PFO (6, 20) . Medical therapies, in theory,
can have a protective effect on recurrent strokes for both PFO-related and unrelated events, whereas device closure presumably protects only against the former. Furthermore, our results do not suggest that putative high-risk anatomical features, such as large PFO size or atrial septal aneurysm, are by themselves very useful at discriminating patients likely to benefit from closure from those unlikely to benefit. Thus, even though a consistent signal for an effect on stroke recurrence is seen in our study, the totality of results Values are % per person-year (events/total person-years) unless otherwise indicated. *Adjusted for age, sex, race, coronary artery disease, diabetes, hypertension, hyperlipidemia, prior stroke, smoking status, index event (stroke versus TIA), hypermobile septum, and PFO shunt size (large versus small). †Adjusted hazard ratios estimated using Cox PH models combined from 10 multiply imputed datasets. In meta-analyses, the source study was included in the model as a stratification term. Tables 1 and 3 . In a head-to-head trial comparing the disc occluder and the umbrella occluder, the umbrella occluder was more commonly associated with device-related complications such as AF and thrombus formation on the device (24); there was also some evidence that the disc occluder device may more effectively prevent cerebrovascular events (25) . A network meta-analysis concluded that the effectiveness of closure depended on the type of device used (5) . Thus, it is reasonable to consider the evidence on each device separately.
Abbreviations as in
Furthermore, analyses restricted to the disc occluder Table 3 for the data included in as-treated analyses. Data for procedural complications were abstracted from the original study publications (see Appendix) and not available for as-treated analysis. ‡Excludes data from the CLOSURE trial.
Abbreviations as in Table 3 . This analysis using individual participant data offered several advantages over prior study-level meta-analyses that were based on the published aggregate results. We were able to harmonize outcome definitions across trials and did not have to rely on numerical approximations when extracting data from trial publications; the availability of person-level data also permitted covariate adjustment, proper handling of missing data, and exploration of effect heterogeneity. These differences presumably explained why our results for some analyses were statistically significant where prior studylevel meta-analyses were not (1) (2) (3) (4) (26) (27) (28) .
STUDY LIMITATIONS. First, the pooled analysis inherited any limitations of the component studies.
Crossover and loss to follow-up in the studies were high relative to the number of events and somewhat more common in the medical arm. Although the ITT effect is consistently estimated in the presence of noncompliance to assigned treatment, selection bias due to loss to follow-up may have affected our analyses. This analysis did not address questions regarding the optimal antithrombotic regimen in patients with PFO and cryptogenic stroke; medical regimens-both for the comparison group and as cotreatments to device implantation-were heterogeneous within and between the included studies.
Observational comparative effectiveness research has shown nonsignificant effects of oral anticoagulation over antiplatelet therapy in these patients (29) .
Newer agents are now under study in the cryptogenic stroke population (NCT02239120; NCT02313909).
Additionally, the trials included in our analysis were designed as prospective, randomized, open, blinded endpoint studies, and it appears that this design may have led to a slight imbalance in referral for endpoint adjudication in the PC trial, although not in CLOSURE I or RESPECT (30) . Finally, most patients were followed for a short time frame of around 2.5 years, and device implantation is essentially a permanent intervention. An observational study comparing closure versus medical therapy using propensity-score matching methods suggested widening benefits over time (31) . 
CONCLUSIONS

